Are Vivanza Biosci. latest results good or bad?

Vivanza Biosciences has reported its financial results for the quarter ending March 2025, which reflect significant challenges in its operational performance. The company's net sales experienced a substantial decline of 89.14% compared to the same quarter last year, indicating a notable contraction in revenue generation.
The operating profit (PBDIT) for this quarter was recorded at Rs -0.96 crore, marking the lowest level in the past five quarters, which suggests persistent operational difficulties. Similarly, the profit before tax (PBT) also reached a low of Rs -1.04 crore, further highlighting the financial strain the company is facing.

Earnings per share (EPS) stood at Rs -0.25, indicating a reduction in profitability for shareholders relative to previous periods. Additionally, the debtors turnover ratio fell to 0.92 times, the lowest in the last five half-yearly periods, which may imply a slowdown in the company's ability to collect receivables efficiently.

As a result of these financial challenges, the company saw an adjustment in its evaluation over the last three months, although the overall outlook remains concerning based on the latest quarterly performance. Overall, the financial data suggests that Vivanza Biosciences is navigating a difficult operational landscape.